

APTUS PHARMA PRIVATE LIMITED

NOTICE

Notice is hereby given that 13th Annual General Meeting of members of **APTUS PHARMA PRIVATE LIMITED** will be held on Saturday, 30th September, 2023 at 11:00 a.m. at the registered office of the company situated at Shed No. 74-75, Raghuvir Estate, NH - 8, Aslali, Ahmedabad - 382427 to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the audited financial statement of the Company for the financial year ended on 31st March, 2023 and the Reports of the Board of Directors and the Auditor's thereon.

For and on behalf of Board of Directors
APTUS PHARMA PRIVATE LIMITED

Date: 05/09/2023
Place: Rajkot


TEJASH M. HATHI
Director
DIN: 03151221

NOTE:

1. The member entitled to attend and vote at the meeting may appoint another member as proxy to attend and vote at the meeting on his or her behalf. The instrument appointing the proxy must be deposited at the registered office of company not later than forty eight hours before commencement of meeting.
2. Members and Proxies attending the Meeting should bring the attendance slip duly filled in for attending the Meeting.
3. Corporate Members intending to send their authorized representatives to attend the AGM are requested to send a certified true copy of the Board Resolution/ Authorisation Letter to the Company, authorizing them to attend and vote on their behalf at the AGM.

ENCL.:

1. Attendance Slip
2. Proxy Form (MGT-11)
3. Route Map

APTUS PHARMA PRIVATE LIMITED

ATTENDANCE SLIP

I certify that I am a registered Member/ Proxy for the registered member of the Company. I hereby record my presence at the Annual general meeting of the Company held Saturday, 30th September, 2023 11:00 a.m at the registered office of the company situated at Shed No. 74-75, Raghuvir Estate, NH - 8, Aslali, Ahmedabad - 382427 Name(s) of Shareholder(s):

_____ (Including joint holders if any)

1. Registered Address of the Sole/ First Named Shareholders:

2. Registered Folio No.: _____

3. Number of Equity Share(s) held: _____

4. Name of Proxy if attending for member: _____

(Signature of Member/Proxy)

Note:

1. Only Member/ Proxy holder can attend the meeting.
2. Members/ Proxy holders are requested to bring this Attendance Slip to the Meeting and hand over the same at the entrance duly signed.
3. Bodies Corporate who are members may attend through their authorized representatives appointed under section 113 of the Companies Act, 2013.

APTUS PHARMA PRIVATE LIMITED

Form No. MGT-11 Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: **U24230GJ2010PTC061957**

Name of the Company: **APTUS PHARMA PRIVATE LIMITED**

Registered Office: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad – 382427

Name of the member (s):

Registered Address:

E-mail Id:

Folio No:

I/We, being the member (s) of shares of the above named company, hereby appoint

1. Name:

Address:

E-mail Id:

Signature:, or failing him

2. Name:

Address:

E-mail Id:

Signature:, or failing him

3. Name:

Address:

E-mail Id:

Signature:

As my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Annual general meeting of the company, to be held **Saturday, 30th September, 2023 11:00 a.m** at the registered office of the company situated at Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad – 382427 and at any adjournment thereof in respect of such resolutions as are indicated below:

Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com

CIN: U24230GJ2010PTC061957, GSTIN: 24AAICA7890D1ZM

APTUS PHARMA PRIVATE LIMITED

Resolution No.

1

2

3

Signed this ____ day of _____ 20 ____

Signature of shareholder


Affix
Revenue
Stamp

Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

APTUS PHARMA PRIVATE LIMITED

Route-map of AGM Venue – Aptus Pharma Private Limited



Regd. Address: Shed No. 74-75, Raghuvir Estate, NH – 8, Aslali, Ahmedabad, Gujarat – 382427, India.
Contact: 76004 27827, **E-mail:** aptuspharma@rediffmail.com, **Website:** www.aptus-pharma.com
CIN: U24230GJ2010PTC061957, **GSTIN:** 24AAICA7890D1ZM

APTUS PHARMA PRIVATE LIMITED

CIN:U24230GJ2010PTC061957

Annual Report for F.Y. 2022-23

Name of Director	Designation
TEJASH M. HATHI (DIN: 03151221)	Director
CHATRABHUJ V. BUTANI (DIN: 03150466)	Director
GHANSHYAM V. PANSURIYA (DIN: 03150975)	Director
KAPILBHAI H. CHANDARANA (DIN: 03151189)	Director

Regd. Address:

Shed No. 74-75, Raghuvir Estate, NH - 8,
Aslali, Ahmedabad, Gujarat - 382427, India.

Contact: 76004 27827

Email: aptuspharma@rediffmail.com

Website: www.aptus-pharma.com

APTUS PHARMA PRIVATE LIMITED

DIRECTORS' REPORT

To,
The Members,

Your Directors have pleasure in presenting their 13th Annual Report on the business and operations of the Company and the accounts for the Financial Year ended **March 31, 2023**.

1. Financial Summary or Highlights:

Particulars	Amount in hundreds	
	F.Y. 2022-23	F.Y. 2021-22
Revenue from operation	13,89,732.14	10,50,666.30
Profit/ (Loss) before interest, depreciation	61,069.47	32,455.03
Less: Interest	9,764.92	8,325.71
Less: Depreciation	18,004.59	9,506.72
Profit/ (Loss) before tax	33,299.96	14,622.60
Less: Provision for Taxation		
Deferred Tax	(1,719.39)	(584.72)
Current Tax	10,542.75	5,127.20
Prior Period Adjustment	(200.79)	-
Profit/ (Loss) for the year	24,275.80	10,080.12
Add: Brought forward from the previous year	20,167.12	10,087.00
Less: Transfer to General Reserve	-	-
Balance carried to the Balance Sheet	44,442.92	20,167.12

2. State of Company's Affair:

The year under review was remained very good for the Company. The revenue for the year has been increased to Rs. 13,89,732.14 hundred as compared to Rs. 10,50,666.30 hundred in the previous year at the same time expenditure has also increased to Rs. 13,56,435.11 hundred as compared to Rs. 10,36,050.15 hundred in the previous year. The company has earned net profit of Rs. 24,275.80 hundred in the current year as compared to the profit of Rs 10,080.12 hundreds in the previous year. Your directors are hopeful for better performance in the upcoming years.

3. Web Address of Annual Return :

Annual Return (Form MGT-7A) will be available on the website of Company i.e. www.apтус-pharma.com.

APTUS PHARMA PRIVATE LIMITED

4. Share Capital:

The paid up equity capital as on 31st March, 2023 was Rs. 30,00,000/-.

5. Board of Directors:

During the year under review, there were no changes in directors and key managerial personnel of the company.

6. Board Meetings:

The meeting of the Board of Directors was duly convened and held 4 (Four) times during the year under review. The intervening gap between any two meetings was within the period prescribed under the Companies Act, 2013.

7. Directors' Responsibility Statement:

Pursuant to Section 134 (5) of the Companies Act, 2013, it is hereby confirmed that:

- a) in the preparation of the annual accounts, the applicable accounting standards have been followed along with proper explanation relating to material departures;
- b) the directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit of the company for the year under review;
- c) the directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- d) the directors have prepared the annual accounts on a going concern basis; and
- e) the directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

8. Statutory Auditors:

As members are aware, pursuant to the provisions of section 139 of the Companies Act, 2013 and the Rules framed there under, M/s. Busa & Associates, Chartered Accountants (FRN: 122574W) was appointed as statutory auditor of the Company for a period of five years at the Annual General Meeting held on 30th September, 2019. M/s. Busa & Associates have confirmed their eligibility to remain continue as the auditor of the Company for their remaining term.

9. Auditors Report:

The Statutory Auditor has issued Audit Reports with unmodified opinion on the Financial Statements of the Company for the year ended 31st March, 2023. The Notes on the Financials Statement referred to in the Audit Report are self-explanatory and therefore, do not call for any further explanation or comments from the Board of Directors.

APTUS PHARMA PRIVATE LIMITED

10. Reporting of Fraud:

There was no instance of fraud during the year under review, which required the Statutory Auditor to report to the Board under Section 143(12) of the Act and Rules framed there under.

11. Particulars of Contracts or Arrangements with Related Parties:

All contracts/ arrangements/ transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. During the year, the Company had not entered into any contract/ arrangement/ transaction with related parties which could be considered material. In view of the above, the requirement of giving particulars of contracts/ arrangements/ transactions made with related parties, in Form AOC-2 are not applicable for the year under review.

12. Material Changes and Commitments:

No material changes and commitments affecting the financial position of the Company occurred between the end of the financial year to which this financial statement relates and the date of this report.

13. Details of Significant and Material Orders Passed by the Regulators, Courts and Tribunals:

No significant and material order has been passed by the regulators, courts, tribunals impacting the going concern status and Company's operations in future.

14. Disclosures under Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013:

The Company is committed to provide a safe and conducive work environment to its employees. The Company has complied with the relevant applicable provisions if any under the Sexual Harassment of Women at Workplace (Prevention, Prohibition & Redressal) Act, 2013.

During the year under review, no case of sexual harassment was reported.

15. Disclosure about Secretarial Standard:

The Directors have devised proper systems to ensure compliance with the provisions of all applicable Secretarial Standards and that such systems are adequate and operating effectively.

APTUS PHARMA PRIVATE LIMITED


Acknowledgements:

Your Board places on record sincere gratitude and appreciation for all the employees. The Board conveys its appreciation for its customers, Shareholders, employees, bankers, auditors, end users, business partners and other business constituents during the year under review.

For and on behalf of Board of Directors
APTUS PHARMA PRIVATE LIMITED

Date: 05/09/2023


Place: Rajkot



TEJASH M. HATHI

Director

DIN: 03151221



GHANSHYAM V. PANSURIYA

Director

DIN: 03150975



Independent Auditors' Report

To,
The Members
APTUS PHARMA PRIVATE LIMITED

REPORT ON THE FINANCIAL STATEMENTS

OPINION

We have audited the accompanying financial statements of **M/S. APTUS PHARMA PRIVATE LIMITED**, which comprise the Balance Sheet as at March 31, 2023, the Statement of Profit and Loss for the year ended 31st March, 2023 and notes to the financial statements including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2023, and its profit/loss for the year ended on that date.

BASIS OF OPINION

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

INFORMATION OTHER THAN THE FINANCIAL STATEMENTS AND AUDITOR'S REPORT THEREON

The Company's Board of Directors and Management is responsible for the preparation of the other information. The other information comprises the information obtained at the date of this auditor's report, but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.



In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITY OF MANAGEMENT AND THOSE CHARGED WITH GOVERNANCE FOR THE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

AUDITORS' RESPONSIBILITY FOR THE AUDIT OF FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and



appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. But not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.



REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, in our opinion and according to the information and explanation given to us, a statement on the matters specified in paragraphs 3 and 4 of the Order is not applicable to the Company.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet and the Statement of Profit and Loss dealt with by this Report are in agreement with the books of accounts.
- (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2023 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) Since the Company's turnover as per last audited financial statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017.
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us
 - i. The Company does not have any pending litigations which would impact its financial position
 - ii. The Company does not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.



iv. (a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

(b) The management has represented, that, to the best of its knowledge and belief, other than as disclosed in the notes to the accounts, no funds have been received by the company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

(c) Based on audit procedures which we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material mis-statement.

v. The company has not declared or paid any dividend during the year.

Rajkot
September 05, 2023

For BUSA & ASSOCIATES
Chartered Accountants

HEMANT BUSA
(Partner)
M. No. 109953
FRN 122574W

UDIN : 23109953BGWQQO8629

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

BALANCE SHEET AS AT 31ST MARCH, 2023.

PARTICULARS	NOTE NO.	AS AT 31.03.2023 AMT. (IN RS. 100's)	AS AT 31.03.2022 AMT. (IN RS. 100's)
I. EQUITY AND LIABILITIES			
(1) Shareholder's funds			
(a) Share Capital	1	30000.00	30000.00
(b) Reserves & Surplus	2	79442.92	55167.12
(c) Money Received Against Share Warrants	-	NIL	NIL
		109442.92	85167.12
(2) Share Application money pending allotment			
	-	NIL	NIL
		NIL	NIL
(3) Non - Current Liabilities			
(a) Long-term borrowings	3	200715.33	106676.93
(b) Deferred tax liabilities(Net)	-	NIL	NIL
(c) Other Long Term liabilities	-	NIL	NIL
(d) Long-term provisions	-	NIL	NIL
		200715.33	106676.93
(4) Current Liabilities			
(a) Short-term borrowings	4	20463.94	19161.26
(b) Trade Payables			
(i) total outstanding dues of micro enterprise and small enterprise; and	5	NIL	NIL
(ii) total outstanding dues of creditors other than micro enterprises and small enterprises		136446.09	91067.53
(c) Other current liabilities	6	142388.36	92064.19
(d) Short-term provisions	7	11603.45	3855.80
		310901.84	208148.78
TOTAL [(1) + (2) + (3)]		621060.09	399992.83
II. ASSETS			
(1) Non-Current Assets			
(a) Property, Plant & Equipment & Intangible Assets			
(i) Property, Plant & Equipment	8	51364.71	34675.17
(ii) Intangible Assets	-	NIL	NIL
(iii) Capital Work- in- Progress	-	NIL	NIL
(iv) Intangible Assets Under Development	-	NIL	NIL
(b) Non-Current Investments	-	NIL	NIL
(c) Deferred Tax Assets (Net)	9	3604.42	1885.03
(d) Long-Term Loans and Advances	-	NIL	NIL
(e) Other Non-Current Assets	10	910.00	910.00
		55879.13	37470.20
(2) Current assets			
(a) Current investment	-	NIL	NIL
(b) Inventories	11	229853.67	139409.84
(c) Trade receivable	12	239824.64	184958.09
(d) Cash and cash equivalents	13	53662.91	26054.12
(e) Short-term loans and advances	14	41839.74	12100.58
(f) Other current assets	-	NIL	NIL
		565180.96	362522.63
Total [(1) +(2)]		621060.09	399992.83

The accompanying notes form an integral part of the accounts - 22

As per our report of even date

For BUSA & ASSOCIATES

Chartered Accountants

HIRANT BUSA

(Partner)

M.No. 109953

FRN 122574W

UDIN: 23109953BGWQQ08629

Rajkot

September 05, 2023



For APTUS PHARMA PRIVATE LIMITED

Director

Tejas

Hathi

DIN:3151221

Director

Ghanshyam

Pansuriya

DIN:3150975

Tejas Hathi

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

MANUFACTURING, PROFIT & LOSS ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2023.

PARTICULARS	NOTE NO.	CURRENT YEAR AMT. (IN RS. 100's)	PREVIOUS YEAR AMT. (IN RS. 100's)
INCOME			
I. Revenue from operation	15	1389732.14	1050666.30
II. Other income	16	2.93	6.45
III. Total Income(I+II)		1389735.07	1050672.75
IV. Expenses:			
(a) Cost of materials consumed	-	NIL	NIL
(b) Purchase of stock-in-Trade	17	566720.09	444223.92
(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	18	(90443.83)	(61173.91)
(d) Employee benefit expense	19	148061.13	87733.55
(e) Finance costs	20	14329.55	9110.10
(f) Depreciation and amortization expense	8	18004.59	9506.72
(g) Other expenses	21	699763.58	546649.77
Total Expenses [(a) to (g)]		1356435.11	1036050.15
V. Profit before exceptional and extraordinary items and tax (III-IV)		33299.96	14622.60
VI. Exceptional items		NIL	NIL
VII. Profit before extraordinary items and tax (V-VI)		33299.96	14622.60
VIII. Extraordinary items		NIL	NIL
IX. Profit before tax (VII-VIII)		33299.96	14622.60
X. Tax expense:			
(1) Current tax		10542.75	5127.20
(2) Deferred tax		(1719.39)	(584.72)
(3) Prior Period Taxation Adjustment		(200.79)	0.00
XI. Profit (Loss) for the period from continuing operation (VII-III)		24275.80	10080.12
XII. Profit / (Loss) for the period from discontinuing operation		NIL	NIL
XIII. Tax expense of discontinuing operations		NIL	NIL
XIV. Profit/ (Loss) for the period from discontinuing operation (after tax) (XII-XIII)		NIL	NIL
XV. Profit (Loss) for the period (XI+XIV)		24275.80	10080.12
XVI. Earning per Equity share:			
(1) Basic		16.62	6.90
(2) Diluted		16.62	6.90

The accompanying notes form an integral part of the accounts - 22

As per our report of even date

For BUSA & ASSOCIATES
Chartered Accountants

HEMANT BUSA

(Partner)

M.No. 109953

FRN 122574W

UDIN: 23109953BGWQQO8629

Rajkot

September 05, 2023



For APTUS PHARMA PRIVATE LIMITED

Director

Tejas

Hathi

DIN:3151224

hathim

Director

Ghanshyam

Pansuriya

DIN:3150975

M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2023.

PARTICULARS	CURRENT YEAR		PREVIOUS YEAR	
	NUMBER OF SHARES (in 100's)	AMOUNT (IN RS. 100's)	NUMBER OF SHARES (in 100's)	AMOUNT (IN RS. 100's)
NOTE "1"				
SHARE CAPITAL				
Authorised				
Equity Shares of Rs. 10 Each With Voting Rights	3000.00	30000.00	3000.00	30000.00
	3000.00	30000.00	3000.00	30000.00
Issued				
Equity Shares of Rs. 10 Each With Voting Rights	3000.00	30000.00	3000.00	30000.00
	3000.00	30000.00	3000.00	30000.00
Subscribed and Fully Paid up				
Equity Shares of Rs. 10 Each With Voting Rights	3000.00	30000.00	3000.00	30000.00
	3000.00	30000.00	3000.00	30000.00

PARTICULARS	CURRENT YEAR	PREVIOUS YEAR
	(AMT in Rs. 100's)	(AMT in Rs. 100's)
NOTE "2"		
RESERVES & SURPLUS		
1 Share Premium	35000.00	35000.00
	"A" 35000.00	35000.00
2 Surplus/(Deficit) in Statement of Profit and Loss		
Opening balance	20167.12	10087.00
Add: Profit / (Loss) for the year	24275.80	10080.12
	"B" 44442.92	20167.12
TOTAL (A+B)	79442.92	55167.12

NOTE "3"
LONG TERM BORROWINGS

TERM LOANS

1 From banks/financial institutions

Secured	105.83	1872.23
Unsecured	12064.53	17034.73

2 From other parties

Secured	NIL	NIL
Unsecured	188544.97	87769.97
	200715.33	106676.93



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2023.

PARTICULARS	CURRENT YEAR (AMT in Rs. 100's)	PREVIOUS YEAR (AMT in Rs. 100's)
NOTE "4"		
SHORT TERM BORROWINGS		
LOAN REPAYABLE ON DEMAND		
1 From banks		
Secured	NIL	NIL
2 From other parties		
Unsecured	NIL	NIL
"A"	NIL	NIL
CURRENT MATURITIES OF LONG TERM BORROWINGS		
From Banks		
1 ICICI Bank -Car Loan (Agreement No. 00037345129)	59.34	897.12
2 Central Bank of India (Agreement. No. 3812062248)	NIL	180.88
3 Central Bank of India (Agreement. No. 3832008015)	1980.00	1980.00
4 HDFC Bank (Agreement No.	6790.85	5792.92
From Financial Institutions		
1 Digikredit Finance Pvt. Ltd.	3108.03	4486.93
2 Bajaj Finance Ltd. (Agreement No. 416BLFGF671615)	8525.72	5823.41
"B"	20463.94	19161.26
TOTAL (A+B)	20463.94	19161.26

NOTE "5"

TRADE PAYABLES

TRADE PAYABLES DUE FOR PAYMENT

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
(i) MSME	-	-	-	-	-
(ii) Others	136235.40	-	118.12	92.57	136446.09
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
TOTAL	136235.40	-	118.12	92.57	136446.09
(i) MSME	-	-	-	-	-
(ii) Others	90855.64	211.89	-	-	91067.53
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
PREVIOUS YEAR	90855.64	211.89	-	-	91067.53



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2023.

PARTICULARS	CURRENT YEAR	PREVIOUS YEAR
	(AMT in Rs. 100's)	(AMT in Rs. 100's)

NOTE "6"

OTHER CURRENT LIABILITIES

1 Statutory Liabilities	15104.37	3194.72
2 Advance Received from Customers	4726.55	2810.58
3 Other Payables	122557.44	86058.89
	142388.36	92064.19

NOTE "7"

SHORT TERM PROVISIONS

1 Provision for employee benefits	0.00	0.00
2 Provision for Taxation	10542.75	5075.80
3 Provision - Others	1060.70	780.00
	11603.45	5855.80

NOTE "8" PROPERTY, PLANT & EQUIPMENT

SR. NO.	NAME OF THE ASSETS	RATE (%)	GROSS BLOCK			ACCUMULATED DEPRECIATION				CLOSING BALANCE		CLOSING BALANCE IN (100)
			BALANCE AS AT 31.03.22	ADDITION DU THE YEAR	DELETION DU THE YEAR	BALANCE AS AT 31.03.23	BALANCE AS AT 31.03.22	ADDITION DU THE YEAR	DELETION DU THE YEAR	BALANCE AS AT 31.03.23	BALANCE 31.03.23	
Own Assets:												
1	Air Conditioner	25.89%	6621.45	8614.56	0.00	15236.11	3236.89	2087.71	0.00	5324.60	9911.51	3384.56
2	Computer	63.16%	14737.85	8240.56	0.00	22978.51	7628.23	6843.45	0.00	14468.68	8509.83	7112.62
3	C.C. TV Camera	25.89%	358.77	3725.16	0.00	4083.93	190.08	444.25	0.00	654.30	3449.53	168.72
4	Furniture & Fixture	25.89%	13198.76	6306.46	0.00	19505.22	2097.37	3927.00	0.00	6024.57	13480.85	11101.39
5	Mobile Phone	25.89%	10835.33	6238.02	0.00	17073.34	2696.04	3145.88	0.00	5841.92	11331.42	8139.28
6	Fan	25.89%	81.00	0.00	0.00	81.00	70.39	2.75	0.00	73.14	7.86	10.61
7	Car Ignite	31.23%	4670.71	0.00	0.00	4670.71	3548.16	350.57	0.00	3898.73	771.98	1122.55
8	Refrigerator	25.89%	1199.16	1398.30	0.00	2597.46	301.93	484.36	0.00	786.29	1811.17	807.23
9	Software	63.16%	195.00	0.00	0.00	195.00	174.78	13.40	0.00	188.18	7.62	21.22
10	Fire Extinguisher	25.89%	36.50	0.00	0.00	36.50	18.00	9.82	0.00	37.68	28.12	37.94
11	Generator	25.89%	1737.29	0.00	0.00	1737.29	667.14	277.06	0.00	944.29	793.09	1070.15
12	Inverter	25.89%	1703.13	170.85	0.00	1873.98	94.23	418.33	0.00	512.55	1361.43	1608.90
			55395.44	34684.11	0.00	90089.55	20720.26	18004.59	0.00	38724.86	51364.71	54675.17
	PREVIOUS YEAR		24083.89	31341.55	0.00	56396.44	11213.64	9506.72	0.00	20720.26	34675.17	12840.35

NOTE "9"

DEFERRED TAX ASSETS

Timing Difference due to depreciation		
Opening Balance	1885.03	1300.31
Add/(Less) : Addition/Deletion during the year	1719.39	584.72
	3604.42	1885.03

NOTE "10"

OTHER NON CURRENT ASSETS

1 Deposit

1 Packing Material Deposit	400.00	400.00
2 Rent Deposit- Hina Bhalodiya	200.00	200.00
3 Rent Deposit- Kanchanben Bhalodiya	310.00	310.00
	910.00	910.00



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

NOTES TO THE BALANCE SHEET AS AT 31ST MARCH, 2023.

PARTICULARS	CURRENT YEAR (AMT in Rs. 100's)	PREVIOUS YEAR (AMT in Rs. 100's)
-------------	------------------------------------	-------------------------------------

NOTE "11"
INVENTORIES

A Finished Goods

1 Finished Goods

"A"

	229853.67	139409.84
	229853.67	139409.84

NOTE "12"
TRADE RECEIVABLES

TRADE RECEIVABLES DUE FOR PAYMENT

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Receivables - Considered good & secured	224492.70	12912.48	1624.27	169.76	625.43	239825
(ii) Undisputed Trade Receivables - Considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables - considered doubtful	-	-	-	-	-	-
TOTAL	224492.70	12912.48	1624.27	169.76	625.43	239825
(i) Undisputed Trade Receivables - Considered good & secured	183654.87	598.16	705.06	0.00	0.00	184958
(ii) Undisputed Trade Receivables - Considered doubtful	-	-	-	-	-	-
(iii) Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
(iv) Disputed Trade Receivables - considered doubtful	-	-	-	-	-	-
PREVIOUS YEAR	183654.87	598.16	705.06	0.00	0.00	184958.09

NOTE "13"
CASH & CASH EQUIVALENTS

1 Cash in Hand	22066.99	20959.74
2 Bank Balance With-		
- Central Bank Of India (Current A/c No. 3194905788)	1713.79	2.42
- HDFC Bank Ltd. (Current A/c 59209879162647)	500.00	500.00
- Central Bank Of India (OD A/c No. 3498339851)	29382.13	4591.96
	53662.91	26054.12

NOTE "14"
SHORT TERM LOANS & ADVANCES

1 Prepaid Expenses	2264.06	1978.83
2 Balance With Government Authorities	2855.82	6458.45
3 Other Loans & Advances	36719.86	3663.30
	41839.74	12100.58



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2023.**

PARTICULARS	CURRENT YEAR (AMT in Rs. 100's)	PREVIOUS YEAR (AMT in Rs. 100's)
NOTE "15"		
REVENUE FROM OPERATIONS		
Sales - GST	1406529.94	1115756.77
Less : Sales Return /Credit Note	16797.80	65090.47
	1389732.14	1050666.30

NOTE "16"
OTHER INCOME

INDIRECT INCOME

1 Kasar & Rounding off

TOTAL

2.93	6.45
2.93	6.45

NOTE "17"
PURCHASE OF STOCK-IN-TRADE

1 Drugs & Medicines Purchases
Less: Purchase Return

588052.94	457785.61
21332.85	13561.69
566720.09	444223.92

NOTE "18"
CHANGES IN INVENTORIES

Finished Goods

Closing Stock
Less: Opening Stock

229853.67	139409.84
139409.84	78235.93
(90443.83)	(61173.91)

NOTE "19"
EMPLOYEE BENEFIT EXPENSES

1 Office & Sales Staff Bonus
2 Office & Sales Staff Salary
3 Provident Fund Expenses
4 Staff Insurance Premium
5 Staff Welfare Expenses

TOTAL

3635.00	1480.00
136192.06	80756.56
5298.42	3190.12
2935.65	NIL
NIL	2306.87
148061.13	87733.55



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2023.**

PARTICULARS	CURRENT YEAR (AMT in Rs. 100's)	PREVIOUS YEAR (AMT in Rs. 100's)
NOTE "20"		
FINANCIAL EXPENSES		
1 Bank Commission & Charges	1605.91	418.63
2 Bank Loan Processing Charges	2832.35	294.47
3 Bank CC Interest	3041.47	722.34
4 Interest On Car Loan - ICICI Bank	49.09	124.44
5 Interest On Late Payment of GST	106.26	NIL
6 Interest On Late Payment of Profession Tax	4.11	59.06
7 Interest On Late Payment of TDS	16.00	12.23
8 Interest On Security Deposit	1704.03	NIL
9 Interest On Term Loan- Bajaj Finance	1703.90	1918.25
10 Interest On Term Loan- CBI	NIL	469.14
11 Interest On Term Loan- Digicredit	1054.15	2644.60
12 Interest On Term Loan- HDFC Bank	2212.28	2446.94
TOTAL	14329.55	9110.10

NOTE "21"

OTHER EXPENSES (Cont...)

(A) DIRECT EXPENSES

1 Cylinder Charges	1212.60	897.00
2 Destroyed Expiry Medicine Expenses	115.37	NIL
3 Discount Expenses	242423.30	115053.07
4 Electricity Expenses	480.27	98.11
5 Freight Expenses	1507.20	1369.55
6 Godown Rent Expenses	NIL	100.00
7 INS Charges	11.72	3.78
8 Inventory Charges	75.65	54.63
9 Packing & Forwarding Expenses	7238.93	340.69
10 Product Approval Charges	13.00	NIL
11 Product Designing Expenses	20.00	386.00
12 Product Development Charges	60.00	30.00
13 Product Expiry Expenses	12322.32	302.12
14 Product Permission Charges	11866.50	7795.50
15 Product Testing Expenses	9022.75	6441.50
16 Rate Difference	35805.53	48231.09
17 Transportation Expenses - Inward	4250.39	4110.47
"A"	326425.53	185213.51



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**NOTES FORMING PARTS TO THE MANUFACTURING, PROFIT AND LOSS
ACCOUNT FOR THE PERIOD ENDED 31ST MARCH, 2023.**

PARTICULARS	CURRENT YEAR (AMT in Rs. 100's)	PREVIOUS YEAR (AMT in Rs. 100's)
NOTE "21"		
OTHER EXPENSES (Cont...)		
(B) ADMINISTRATIVE AND SELLING EXPENSES		
1 Accounting Salary	2640.00	2640.00
2 Advertisement Expenses	10697.15	3932.80
3 Audit Fees	400.00	290.00
4 Awareness Programmes Expenses	4258.76	NIL
5 Bad Debts	NIL	1265.37
6 Car Assoceries & Maintenance Expenses	406.20	NIL
7 Car Insurance Expenses	162.77	NIL
8 Commission Expenses	67648.67	54971.12
9 Computer & Printer Repairing Expenses	1499.72	1279.60
10 Conference & Meeting Expenses	15291.89	16190.03
11 Conveyance Expenses	2880.00	1440.00
12 Directors Remuneration	21465.00	15668.75
13 Discount Expense on Payments	22467.85	13627.90
14 Donation	1290.00	3330.00
15 Driver Salary Expenses	2460.00	2280.00
16 GST Return Late Filing Fees	56.00	153.50
17 Insurance Expenses	363.72	1929.63
18 Legal Fees	3457.80	2830.00
19 Membership Fees	47.52	47.52
20 Miscellaneous Expenses	1201.51	300.20
21 Office Expenses	2972.41	9614.19
22 Office Rent Expenses	3216.00	3996.00
23 Packing Material Expenses	NIL	1187.88
24 Postage & Courier Expenses	6926.18	3962.47
25 Profession Tax	96.00	25.20
26 Professional Fees	NIL	100.00
27 Repairs & Maintenance Expense (Electric)	NIL	428.93
28 ROC Fees	61.00	31.00
29 Sales Promotion Expenses	141715.98	168158.82
30 Software Expenses	NIL	182.20
31 Stationery & Printing Expenses	7847.21	15366.74
32 Telephone Expenses	330.48	156.77
33 Transportation Expenses - Outward	273.30	1922.45
34 Travelling Expenses (Field Staff)	49866.06	32356.51
35 Vehicle Petrol & Repairing Expenses	1338.87	1770.68
"B"	373338.05	361436.26
TOTAL (A+B)	699763.58	546649.77



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

a. SIGNIFICANT ACCOUNTING POLICIES

1. ACCOUNTING METHOD

The Company recognizes all income and expenditure having a material bearing on the financial statements on accrual basis. The financial statements are prepared in accordance with Accounting Standards issued by the Institute of Chartered Accountants of India and the provisions of the Companies Act, 2013 as adopted consistently by the company.

2. ACCOUNTING CONVENTION

The financial statements are prepared under the historical cost convention ignoring changes, if any, in the purchasing power of money.

3. PROPERTY, PLANT & EQUIPMENT

Property, Plant & Equipment are stated at the cost of acquisition. The cost of asset includes other direct /indirect and incidental cost incurred to bring them into their present location. The Company has not revalued its property, plant and equipment (including right of use asset) during the year.

4. PRIOR PERIOD, EXTRA ORDINARY AND EXCEPTIONAL ITEMS

- a) Items of Incomes or Expenses which aroused in the current year but the conditions, events or evidences for those transactions relates to one or more prior periods are separately disclosed in the Financial Statements.
- b) The items of Incomes or Expenditure which does not relates to ordinary business activities are classified as Extra ordinary items in the Financial Statements.
- c) Income or Expenditures which relates to ordinary business activities but are exceptionally high or low as compared to one or more comparatives are classified as Exceptional items.
- d) There is no change in any accounting policy or accounting estimates or the enterprise which materially affect the Financial Statements of the enterprise.

There are no prior period, extra ordinary and exceptional items during the year under audit.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22 (Contd...)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

5. DEPRECIATION

Depreciation on Property, Plant & Equipment is provided by complying the provisions contained in schedule- II of the Companies Act, 2013.

- a) Depreciation is provided using Written Down Value Method, after retaining residual value at the rate of 5% of the cost, over the useful lives of the assets prescribed in schedule-II of the Act.
- b) In case of assets purchased during the year, Depreciation is provided on prorata basis on the basis of useful lives prescribed in Schedule-II.

6. BORROWING COST

Borrowing costs that are attributable to the acquisition or construction of qualifying assets are capitalized as part of the cost of such asset. All other borrowing costs are charged to the revenue. There are no borrowing costs capitalized during the year under audit.

7. REVENUE RECOGNITION

The revenues are recognized as and when accrued and when it is reasonably certain that the ultimate collection will be made in respect of principal activity of business. In other cases revenue is recognized when right to receive income is established.

8. FOREIGN CURRENCY TRANSACTIONS

There are no transactions in foreign currency entered into by the company during the year under consideration.

9. GOVERNMENT GRANTS/INCENTIVES

Company has not received any Government Grants during the year under consideration.

10. EMPLOYEE BENEFITS

Provident fund: Contribution as required under the statute/rules is made to the Government Provident Fund.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE- 22 (Contd...)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

11. EARNING PER SHARE

As per the Accounting Standard issued by ICAI the basic earning/(loss) are calculated by dividing the Net Profit/Loss after Taxation for the year, which is attributable to the equity share holders, is Rs. 16.62. The number of shares used in computing the basic earnings per share is the weighted average number of shares outstanding during the year.

12. TAXES ON INCOME

- a) Provision for income tax is made on the basis of taxable income for the year at current rates.
- b) Tax expense comprises of current Tax, Fringe Benefit Tax and Deferred Tax at the applicable enacted or substantively enacted rates.
 - Current tax represents the amount of Income tax payable/recoverable in respect of the taxable income/loss for the reporting period.
 - Deferred tax represents the effect of timing difference between taxable income and accounting income for the reporting period that originates in one period and are capable of reversal in one or more subsequent periods. The deferred tax asset is recognized and carried forward only to the extent that there is a reasonable certainty the asset will be realized in future. However, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is virtual certainty of realization of assets.

13. SEGMENT REPORTING

As the company's business activities will fall within a single primary business segment, the disclosure requirements of Accounting Standard 17 "Segment Reporting" issued by the ICAI are not applicable.

14. PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

A provision is recognized when an enterprise has present obligations as a result of past event and is probable that an outflow of resources will be required to settle the obligation in respect of which reliable estimates can be made.

Provisions are not discounted to their present value and are determined based on management estimates required to settle the obligations at the balance sheet date. These are reviewed at the balance sheet date and adjusted to reflect the current management estimates.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

15. IMPAIRMENT OF ASSETS

The Company assess at Balance Sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the assets. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the profit and loss account. If at the balance sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount.

b. NOTES ON ACCOUNTS

1. LONG TERM BORROWINGS

- 1) The Company has used the borrowings from banks and financial institutions for the specific purpose for which it was taken as at the reporting date.
- 2) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies (ROC) beyond the statutory period except Car Loan from ICICI Bank.

2. SHORT TERM BORROWINGS

- 1) The Company has not been sanctioned working capital limits in excess of five crore rupees in aggregate, from banks or financial institutions on the basis of security of current assets at any point of time during the year.
- 2) The Company is not declared as wilful defaulter by any bank or financial institution or other lenders.

3. INVENTORIES

- 1) Inventories are taken, valued and certified by the Management.
- 2) Inventories are valued at cost or net realizable value whichever is lower following FIFO Method.
- 3) The Company has physically verified the inventories at reasonable intervals and there are no discrepancies of 10% or more in the aggregate for each class of inventory noticed during such verification.

4. TRADE RECEIVABLES

- 1) Trade receivables are neither due from directors or other officers of the Company either severally or jointly with any other person, nor any trade or other receivables are due from firms or private companies respectively in which any director is a partner, a director or a member.
- 2) There are no receivables due from the related parties.
- 3) Refer Note No. 12 for the ageing schedule of Trade Receivables



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

5. CURRENT ASSETS, LOANS AND ADVANCES AND LIABILITIES

- 1) In the opinion of the Board of Directors, the value on realization of current assets, loans and advances, if realized in the ordinary course of the business, shall not be less than the amount, which is stated, in the current year Balance sheet. The provision for all known liabilities is reasonable and not in excess of the amount considered reasonably necessary.
- 2) The Company has not granted any loan or advance in the nature of loan to promoters, directors, KMPs and other related parties that are repayable on demand or without specifying any terms or period of repayment.

6. DISCLOSURE REQUIREMENT FOR SUNDRY CREDITORS COVERED UNDER MSME ACT, 2006

As informed by the management, the company has circulated confirmation for the identification of suppliers registered under the Micro, Small and Medium Enterprises Development Act, 2006. *The company however has not received any confirmation from suppliers regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence disclosures, relating to amounts unpaid, if any, as at the year end together with interest paid/payable as required under the said Act have not been given in our financial statement.*

7. DISCLOSURE UNDER SECTION 73 OF COMPANIES ACT, 2013

In view of provisions of section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 and General Circular No. 05/2015 dated 30th March, 2015 issued by Ministry of Corporate Affairs, Government of India, disclosures relating to unsecured loans and deposits accepted are given as under.

The company has not accepted unsecured loans from "persons other than directors or their relatives" which is considered as deposits as per the provisions of companies Act, 2013.

8. PARTICULARS OF RAW MATERIALS, WORK IN PROGRESS, OTHER MATERIALS AND FINISHED GOODS UNDER BROAD HEADS

As taken, valued and certified by management, in view of disclosure requirements of revised schedule VI regarding disclosure of Raw Materials, Work in Process and Finished Goods under broad heads, the items wise details in respect of each of item is not presented as the same is not made available by the management.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

9. DEFERRED TAX ASSETS/LIABILITIES

Provision for current tax is made after taking into consideration benefits admissible under the provisions of income tax Act, 1961. Deferred tax resulting from timing difference between book and taxation profit is accounted for using the tax rates and laws that have been enacted or substantively enacted on the date of balance sheet. The deferred tax asset and liabilities are recognized and carried forward only to the extent that there is reasonable certainty that the assets will be realized in future. Break up of Net Deferred Tax Liability/(Asset) into major components is given below:

(Amt. in Rs. '00)				
Sr. No.	Particulars	Deferred tax (asset)/Liability as on 01.04.2022	Add/(Less) Current Year	Deferred tax (asset)/Liability as on 31.03.2023
1.	Depreciation (Timing Difference)	(1885.03)	1719.39	(3604.42)
2.	Disallowance U/s	-	-	-
	TOTAL	(1885.03)	1719.39	(3604.42)

10. DIRECTOR'S REMUNERATION

Amount of Rs. 21,465.00 hundreds has been given to Directors by way of Remuneration during the financial year covered under audit.

11. AUDITOR'S REMUNERATION

Auditor's Remuneration has been provided as below:

		(Amt. in Rs. '00)	
		Remuneration	
Sr. No.	Particulars	Current Year	Previous Year
1.	Statutory Audit Fees	205.00	185.00
2.	Tax Audit Fees	65.00	65.00
	Total	270.00	250.00

12. FOREIGN EXCHANGE EARNING AND OUTGO

The company has not earned and spent major foreign exchange during the financial year covered under audit.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.

13. RELATED PARTY TRANSACTIONS

As per Accounting Standard 18, disclosure of transaction with related parties as defined in Accounting Standard are given below:

Sr. No.	Name of Related Parties	Relationship	Nature of Transaction	Amount (in Rs. 00)
1	Tejasbhai M. Hathi	Key Managerial Personnel	Director's Remuneration	8400.00
2	Ghanshyambhai Pansuriya	Key Managerial Personnel	Director's Remuneration	5415.00
3	Kapilbhai Chandarana	Key Managerial Personnel	Director's Remuneration	7650.00
4	Yeshaben G. Pansuriya	Key Managerial Personnel's Relative	Salary	3486.00
5	Grishmaben K. Chandarana	Key Managerial Personnel's Relative	Salary	2640.00
6	Yeshaben G. Pansuriya	Key Managerial Personnel's Relative	Conveyance Expense	480.00
7	Tejasbhai M. Hathi	Key Managerial Personnel	Unsecured Loan taken of Rs. 295750.00 and repaid during the year of Rs.199975.00. O/S as on 31.03.2023 Rs. 151531.53	
8	Ghanshyambhai Pansuriya	Key Managerial Personnel	Unsecured Loan of Rs. 5000.00 taken during the year. O/S as on 31.03.2023 Rs. 5000.00	

14. CONFIRMATION

Balance of Bank and Cash, Loans & Advances, Sundry Debtors & Sundry Creditors are subject to confirmation

15. GRATUITY

Company has not made the provision for gratuity in the books of accounts.

16. PREVIOUS YEAR'S FIGURES

Previous year's figures have been regrouped/rearranged wherever necessary to make them comparable with the figures of the current year.



APTUS PHARMA PRIVATE LIMITED: RAJKOT

NOTE-22 (Contd..)

STATEMENT OF SIGNIFICANT ACCOUNTING POLICIES AND NOTES FORMING PART TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31ST MARCH, 2023.


17. ROUNDING OFF OF FIGURES

Figures have been rounded off to hundreds upto two decimals.

18. OPENING BALANCES

Opening Balances are taken from the audited balance sheet of the last year.


**For BUSA & ASSOCIATES
Chartered Accountants**


**HEMANT BUSA
(Partner)
M.No. 109953
FRN: 122574W**



FOR APTUS PHARMA PRIVATE LIMITED


**(DIRECTOR)
Tejas
Hathi
DIN:3151221**


**(DIRECTOR)
Ghanshyam
Pansuriya
DIN:3150975**

**Rajkot
September 05, 2023**

APTUS PHARMA PRIVATE LIMITED: RAJKOT

Additional regulatory and other information as required by the Schedule III to the Companies Act 2013

1) Proceedings under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

There are no proceedings initiated or are pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

2) Relationship with Struck off Companies

The Company did not have any transactions with Companies struck off under Section 248 of Companies Act, 2013 or Section 560 of Companies Act, 1956 considering the information available with the Company.

3) Compliance with number of layers of companies

The Company do not have any parent company and accordingly, compliance with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable for the year under consideration.

4) Accounting Ratios- Refer to the Annexure attached.

5) Scheme of arrangements

There are no Scheme of Arrangements approved by the Competent Authority in terms of sections 230 to 237 of the Companies Act, 2013 during the year.

6) Advance or loan or investment to intermediaries and receipt of funds from intermediaries

The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

The company has also not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.




7) Undisclosed Income

The Company do not have any transaction which are not recorded in the books of accounts that has been surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 during any of the years.

8) Details of Crypto Currency or Virtual Currency

The Company did not trade or invest in Crypto Currency or virtual currency during the financial year. Hence, disclosures relating to it are not applicable.


For BUSA & ASSOCIATES
Chartered Accountants


HEMANT BUSA
(Partner)
M.No. 109953
FRN: 122574W



FOR APTUS PHARMA PRIVATE LIMITED


(DIRECTOR)
Tejas
Hathi
DIN:3151221


(DIRECTOR)
Ghanshyam
Pansuriya
DIN:3150975

Rajkot
September 05, 2023

M/S APTUS PHARMA PRIVATE LIMITED: RAJKOT

Annexure : 4. ACCOUNTING RATIOS

SR. NO.	PARTICULARS	NUMERATOR (in Rs. 100's)	DENOMINATOR (in Rs. 100's)	AS AT 31ST MARCH 2023	AS AT 31ST MARCH 2022	VARIANCE (%)
1	CURRENT RATIO	565181	310902	1.82	1.74	4.38%
2	DEBT EQUITY RATIO	511617	109443	4.67	3.70	26.46%
3	DEBT SERVICE COVERAGE RATIO	65634	34793	1.89	1.18	60.44%
4	RETURN ON EQUITY RATIO	24276	109443	22.18%	11.84%	87.41%
5	INVENTORY TURNOVER RATIO	326426	184632	1.77	1.70	3.88%
6	TRADE RECEIVABLES TO RATIO	1389732	212391	6.54	6.16	6.31%
7	TRADE PAYABLES TO RATIO	566720	113757	4.98	6.07	-17.94%
8	NET CAPITAL TO RATIO	1389732	109443	12.70	12.34	2.93%
9	NET PROFIT RATIO	24276	1389732	1.75%	0.96%	82.07%
10	RETURN ON CAPITAL EMPLOYED	41361	310158	13.34%	11.96%	11.48%
11	RETURN ON INVESTMENT			NA		

NOTE : Variance in Return on Equity, Net Profit & Return on Capital Employed Ratio is due to decline in profits of the company.



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**SUB NOTE TO NOTE "1"
SHARE CAPITAL**

(i) Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:

Particulars	Opening Balance	Fresh issue	Other changes (give details)	IN (100)
				Closing Balance
Equity shares with voting rights				
Year ended 31 March, 2023				
- Number of shares	3000.00	-	-	3000
- Amount (F.V. of Rs.10 Each)	30000.00	-	-	30000
Year ended 31 March, 2022				
- Number of shares	1250.00	1750.00	-	3000
- Amount (F.V. of Rs.10 Each)	12500.00	17500.00	-	30000

(ii) Details of shares held by each shareholder cum promoter holding more than 5% shares:

Class of shares / Name of shareholder	As at 31 March, 2023		As at 31 March, 2022	
	Number of shares held	% holding in that class of shares	Number of shares held	% holding in that class of shares
<u>Equity shares with voting rights</u>				
1. Tejasbhai M. Hathi	450.00	15.00%	450.00	15.00%
2. Chatrabhuj V. Butani	450.00	15.00%	450.00	15.00%
3. Kapilbhai H. Chandarana	450.00	15.00%	450.00	15.00%
5. Riddhish Natwarlal Tanna	300.00	10.00%	300.00	10.00%
6. Gaurang Raneshbhai Thakkar	300.00	10.00%	300.00	10.00%
7. Milly Chetan Lalseta	300.00	10.00%	300.00	10.00%
8. Kripali Mayankbhai Thakkar	300.00	10.00%	300.00	10.00%
9. Kunjal Piyush Unadkat	300.00	10.00%	300.00	10.00%



SUB NOTE TO NOTE '3'

(i) Details of terms of repayment for the other long-term borrowings and security provided in respect of the secured other long-term borrowings:

(j) Term Loans From Banks & Financial Institutions

(Amt. Rs. in 100)

Sr. No.	Particulars	Terms of repayment and security*	As at 31 March, 2023			As at 31 March, 2022		
			Total	Current	Net Balance	Total	Current	Net Balance
Term loans from banks:								
1	ICICI Bank - Car Loan (Agreement No. 00037345129)	Car Ignis (Car Refinance Loan) (Payable in 60 EM)	59.34	59.34	NIL	907.37	897.12	10.25
2	Central Bank of India (Agreement, No. 3812062248)	Cent Covid 19 Sahayata (Secured against current assets)	NIL	NIL	NIL	180.88	180.88	NIL
3	Central Bank of India (Agreement, No. 3832008015)	Cent GECL (Secured against current assets)	2085.83	1980	105.83	3841.98	1980	1861.98
A			2145.17	2039.34	105.83	4930.23	3058	1872.23
Term loans from banks (unsecured):								
1	HDFC Bank (Agreement No. 113654739)	Unsecured (Payable in 36 EM)	10613.13	6790.85	3822.28	16406.05	5792.92	10613.13
B			10613.13	6790.85	3822.28	16406.05	5792.92	10613.13
Term loans from financial institutions (unsecured):								
1	Digikredit Finance Pvt. Ltd. (Agreement)	Unsecured (Payable in 36 EM)	3108.03	3108.03	NIL	7594.96	4486.93	3108.03
2	Bajaj Finance Ltd. (Agreement No. 416BLPQP671615)	Unsecured (Payable in 36 EM)	NIL	NIL	NIL	9136.98	5823.41	3313.57
3	Bajaj Finance Ltd. (Agreement No. P416PBL5411354)	Unsecured (Payable in 24 EM)	16767.97	8525.72	8242.25	NIL	NIL	NIL
C			19875	11633.75	8242.25	16731.94	10310.34	6421.6
Total - Term loans from banks & financial institutions (A+B+C)			32634.3	20463.94	12170.36	38068.22	19161.26	18906.96

(ii) Term loans from other parties:

(Amt. Rs. in 100)

Sr. No.	Particulars	Terms of repayment and security*	As at 31 March, 2023		As at 31 March, 2022	
			Secured	Unsecured	Secured	Unsecured
A From Directors						
1	Mr. Tejasbhai M. Hathi	(Without predetermined terms of repayment and interest)	NIL	151531.53	NIL	55756.53
2	Mr. Kapilbhai H. Chandarana		NIL	10663.40	NIL	10663.40
3	Mr. Chatrabhujbhai V. Butani		NIL	3600.04	NIL	3600.04
4	Ghanshyam Pansuriya		NIL	5000.00	NIL	NIL
A			NIL	170794.97	NIL	70019.97
B From Share holders & their relatives						
1	Gaurang Thakkar	(Repayable in 3 Years)	NIL	3550.00	NIL	3550.00
2	Kripal M. Thakkar		NIL	3550.00	NIL	3550.00
3	Kunjai Anadkat		NIL	3550.00	NIL	3550.00
4	Milly C. Lalseta		NIL	3550.00	NIL	3550.00
5	Riddhish Tanna		NIL	3550.00	NIL	3550.00
B			NIL	17750.00	NIL	17750.00
Total - Term loans from other parties			NIL	188544.97	NIL	87769.97



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

SUB NOTES FORMING PARTS OF THE NOTES TO THE BALANCE SHEET AS AT 31.03.2023

**SUB NOTE TO NOTE "4"
SHORT TERM BORROWINGS**

(i) Details of security for the secured short-term borrowings:

IN (100)

SR. NO.	Particulars	Nature of security	As at 31st March, 2023		As at 31st March, 2022	
			Secured	Unsecured	Secured	Unsecured
			Amt. in Rs.	Amt. in Rs.	Amt. in Rs.	Amt. in Rs.
1	Loan Repayable on Demand <u>From Banks:</u> Central Bank of India (OD A/c No. 3498339851)	Stock & Book Debts	NIL	NIL	NIL	NIL
	Total - from banks		NIL	NIL	NIL	NIL

**SUB NOTE TO NOTE " 5 "
ACCEPTANCES**

TRADE PAYABLES DUE FOR PAYMENT

Particulars	Outstanding for following periods from due date of payment				
	Less than 1 year	1-2 years	2-3 years	More than 3 year	Total
(i) MSME					
(ii) Others					
1 Accreation INC.	351.12	0.00	0.00	0.00	351.12
2 Accreation Nutraveda Pvt. Ltd.	1543.54	0.00	0.00	0.00	1543.54
3 Accreation Pharmaceuticals	32782.50	0.00	0.00	0.00	32782.50
4 Akums Drugs & Pharmaceuticals Ltd.	1029.50	0.00	0.00	0.00	1029.50
5 Alps Communication Pvt.Ltd.	3533.03	0.00	0.00	0.00	3533.03
6 Antila Lifesciences Pvt. Ltd.	0.00	0.00	112.83	0.00	112.83
7 Avyukta Lifecare	2107.32	0.00	0.00	0.00	2107.32
8 Dizan Pharma	0.00	0.00	5.29	0.00	5.29
9 Hiral Labs Ltd.	2752.54	0.00	0.00	0.00	2752.54
10 Logos Pharma	25135.23	0.00	0.00	0.00	25135.23
11 Malik Lifesciences Pvt. Ltd.	20902.17	0.00	0.00	0.00	20902.17
12 Neuron Pharma Pvt.Ltd.	846.81	0.00	0.00	0.00	846.81
13 Pharma Co Healthcare	0.00	0.00	0.00	92.57	92.57
14 Pure & Cure Healthcare Pvt. Ltd.	2734.28	0.00	0.00	0.00	2734.28
15 Shri Hari Pharmaceuticals	40400.01	0.00	0.00	0.00	40400.01
16 Theon Pharmaceuticals	2117.35	0.00	0.00	0.00	2117.35
(iii) Disputed Dues - MSME	-	-	-	-	-
(iv) Disputed Dues - others	-	-	-	-	-
TOTAL	136235.40	0.00	118.12	92.57	136446.09



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023**

PARTICULARS	AMT.(RS. IN 100)
SUB NOTE TO NOTE "6"	
OTHER CURRENT LIABILITIES	
STATUTORY LIABILITIES	
1 CGST Payable	4618.67
2 IGST Payable	2.97
3 SGST Payable	4618.66
4 CGST Credit Receivable Defference	10.59
5 SGST Credit Recessivable Defference	10.59
6 TCS Payable	128.59
7 TDS Payable	
- On Purchase	260.63
- On Works Contract	251.07
- On Professional Fees	693.30
- On Commission	2075.43
- On Interest	67.73
- On Salary	605.00
8 Providend Fund - Employer's Contribution	492.54
- Employee's Contribution	442.60
9 Profession Tax Payable	826.00
	15104.37
ADVANCE RECEIVED FROM CUSTOMERS	
1 Asclepius Health World	437.92
2 Little Miracles Pharmacy	7.99
3 Maruti Medical	407.32
4 Param Pharmacy - A Unit of Shree Giriraj Lifecare	1060.92
5 Shree Giriraj Medicines	1145.79
6 Yuvee Enterprise	1666.61
	"A" 4726.55
OTHER LIABILITIES	
SUNDRY CREDITORS FOR EXPENSES	
1 A to Z Holidays	72.00
2 Accretion Nutraveda Pvt. Ltd.	15770.57
3 Accretion Pharmaceuticals	19788.16
4 Bagdai & Associates (Professional Fees)	130.00
5 Bansi Industries	7064.42
6 Bansi Packaging	1074.91
7 Baywood Hotels India Pvt. Ltd.	105.00
8 Chirag Tusharbhair Kanani	5113.28
9 Computer Bazar	13.00
10 Daffocare Research Laboratory LLP	710.37
11 Durga Prakashan	302.40
12 Graphics Point	50.74
13 Heena Tusharbhair Kanani	5349.84
14 Hetalben Shah	10.00
15 Hotel Anjali Palace	33.60
	TOTAL C/F 55588.29



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023**

PARTICULARS

AMT.(RS. IN 100)

SUB NOTE TO NOTE "6"

*** OTHER CURRENT LIABILITIES (Contd.)**

TOTAL B/F	55588.29
16 Hotel Bhabha King Store	74.45
17 Hotel Milestone	27.72
18 Hotel The Grand Bansi	13.99
19 Jagira Ananta Elite	525.71
20 Khushboo Tusharbhai Kanani	5828.65
21 Milan Print Pack	1422.83
22 Om Logistics Ltd.	325.57
23 Peter England Showroom	575.69
24 Phoenix Hospitality	1372.18
25 Pratap Industries Hotel Kalyan	39.20
26 Rajdeep Overseas Pvt.Ltd.	30.36
27 Regency Lagoon Resort	782.50
28 Ronak Enterprise	419.97
29 Sayaji Hotels Management Ltd.	202.30
30 Shah Uni Agency	29642.15
31 Shiv Hotel	27.99
32 Shree Krishna Plastic	582.66
33 Shree Mahavir Mart	10.55
34 The Besil Inn.	89.60
35 The Ummad - Ahemdabad	81.19
36 Vaibhav Analytical Services	2768.04
37 Vallabh Printers	993.86
38 Vardhman Creation	171.00
39 Wave Analytical & Research Center	1749.60
40 West Inn Ltd.	74.25
"C"	103420.30

SALARY PAYABLE

1 Aaqib Munshi	293.00
2 Abhishek Metaliya	615.73
3 Amitkumar Dave	218.00
4 Bhartiben Chandubhai Sisha	500.00
5 Chandu Shisha	800.03
6 Dipak Parmar	549.04
7 Dipesh Dalal	361.48
8 Gaurang Thakar	661.74
9 Ghanshyam Katariya	362.20
10 Ghanshyam Pansuriya	524.80
TOTAL C/F	4886.02



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023**

PARTICULARS	AMT.(RS. IN 100)
SUB NOTE TO NOTE "6"	
OTHER CURRENT LIABILITIES (Contd.)	
	TOTAL B/F
	4886.02
11 Hardik Patel	450.94
12 Haribhai Sabhad	141.00
13 Hitesh shah	495.00
14 Imran Wadaliwala	478.18
15 Kabira Akesh	125.00
16 Kailashbhai Parmar	200.00
17 Kalpeshbhai Rudani	1990.00
18 Kapilbhai Chandrana	384.20
19 Mayur Dabhi	10.00
20 Mayur Gondaliya	270.00
21 Mitesh Parekh	225.00
22 Nirav Pandya	520.43
23 Niravbhai Parmar	328.00
24 Parth Mansukbhai Suthar	214.25
25 Rahul Yadav	260.47
26 Rakesh Patel	566.88
27 Ritesh Mandaviya	712.29
28 Ronak Joshi	806.01
29 Sagar Joshi	721.32
30 Satishkumar Veeresh Pandey	214.20
31 Siddharth Makwana	736.69
32 Tejas Hathi	2179.47
33 Tejas Hathi - Reimburshment	96.42
34 Tejas Panchal	131.70
35 Vikas Pathak	313.60
36 Yogeshkumar Jasvantlal Rajgor	452.19
	"D"
	17909.26
SUNDRY CREDITORS FOR FIXED ASSETS	
1 Divine Electronics	670.00
2 Ram Appliances Porbandar	290.00
3 Raghuvir Furniture Rajkot	54.28
4 Winstar Power System	213.60
	"E"
	1227.88
	TOTAL (A+B+C+D+E)
	109374.73
SUB NOTE TO NOTE "7"	
SHORT TERM PROVISIONS	
PROVISIONS OTHERS	
1 Audit Fees Payable	270.00
2 Electricity Expenses Payable	30.70
3 Legal Fees Payable	760.00
	1060.70



SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023

PARTICULARS

AMT. (RS. IN 100)

SUB NOTE TO NOTE " 12 "

TRADE RECEIVABLES

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade Receivables - Considered good						
1 Aakash Medical Agencies	5080.22	-	-	-	-	5080.22
2 Anant Agencies	8562.26	-	-	-	-	8562.26
3 Ansh Pharma	1727.65	-	-	-	-	1727.65
4 Apex Pharma	-	-	-	-	625.43	625.43
5 B M Pharma	74.71	-	-	-	-	74.71
6 Baria Drugs Distributors	2563.92	-	-	-	-	2563.92
7 Brahmani Pharma	3133.93	-	5.27	-	-	3139.2
8 Chirag Enterprise	8360.21	-	-	-	-	8360.21
9 Deep Distributors	943.80	-	-	-	-	943.8
10 Dr. A. H. Hingora	-	-	329.93	-	-	329.93
11 General medical Store (bombay)	1549.68	-	-	-	-	1549.68
12 Gopinath Agencies	-	-	84.77	169.76	-	254.53
13 Gujarat Pharma	4796.66	-	-	-	-	4796.66
14 Harsh Agencies	15087.36	-	-	-	-	15087.36
15 J. Lalubhai & Sons	3947.15	-	-	-	-	3947.15
16 Janta Drug Agency	13793.16	-	-	-	-	13793.16
17 Jivandhara Pharma Pvt. Ltd.	615.96	-	-	-	-	615.96
18 K. D. Distributors	5585.54	-	-	-	-	5585.54
19 Kashiwanjan Medical Store	10726.20	-	-	-	-	10726.2
20 Leo Pharma	11056.82	-	-	-	-	11056.82
21 Lucky Corporation	789.96	-	-	-	-	789.96
22 Maheshwari Medical Agency	14884.80	-	-	-	-	14884.8
23 Manish Medical Corporation	919.26	288.23	-	-	-	1207.49
24 Mexon Pharma	11312.50	-	-	-	-	11312.5
25 Mother Agencies	441.97	-	-	-	-	441.97
26 National Pharma Distributors	3417.11	-	-	-	-	3417.11
27 Neel Distributors	8186.53	-	-	-	-	8186.53
28 Nirav Parmar	-	-	855.40	-	-	855.4
29 Omnitech Engineering	-	-	76.90	-	-	76.9
30 Parash Medicals Center	1418.91	-	-	-	-	1418.91
31 Parash Pharma Distributors	1052.74	-	-	-	-	1052.74
32 Parikh Medical Store	142.85	-	-	-	-	142.85
33 Patel Drug House	1514.16	-	-	-	-	1514.16
34 Pavan Medical Store	-	-	102.23	-	-	102.23
35 Radhakrishna Medical Agencies	2991.98	-	-	-	-	2991.98
36 Rajadhiraj Pharma	10.06	-	-	-	-	10.06
37 Rapid Medico	2836.89	-	-	-	-	2836.89
38 Relief Drug Agency	13087.68	-	-	-	-	13087.68
39 Royal Distributors	6733.24	-	-	-	-	6733.24
40 Rx Pharma	1258.34	-	-	-	-	1258.34
41 S. P. Pharma Agency	4319.98	-	-	-	-	4319.98
42 Santram Pharma Pvt Ltd.	1955.93	-	-	-	-	1955.93
43 Siddharth Medico	852.57	-	-	-	-	852.57
44 Soham Medical Agency	8708.96	-	-	-	-	8708.96
45 Tapi Drugs House	2584.57	-	-	-	-	2584.57
46 Vyom Medical Store	-	-	169.77	-	-	169.77
47 We- Cure Pharmaceuticals	37466.48	12624.25	-	-	-	50090.73
(ii) Undisputed Trade Receivables - Considered doubtful						
(iii) Disputed Trade Receivables - Considered Good						
(iv) Disputed Trade Receivables - considered doubtful						
TOTAL	224492.70	12912.48	1624.27	169.76	625.43	239824.64



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023

PARTICULARS

AMT. (RS. IN 100)

SUB NOTE TO NOTE " 14"

SHORT TERM LOANS & ADVANCES

PREPAID EXPENSES

1 Prepaid Insurance - Employee	1920.37
2 Prepaid Insurance - Software	248.00
3 Prepaid Insurance - Stock	26.05
4 Prepaid Insurance - Vehicle	69.64
	<u>2264.06</u>

BALANCE WITH GOVERNMENT AUTHORITIES

1 Tax Collected at Source (A.Y. 2023-24)	75.46
2 Tax Deducted at Source (A.Y. 2023-24)	2772.91
3 Excess TDS Paid	2.10
4 IGST Credit Receivable Defference	5.35
	<u>2855.82</u>

OTHER LOANS AND ADVANCES

1 7th Sense Concepts	250.00
2 Akesh Kabira	180.00
3 Ap Life Care	22.00
4 Aranya Hospitality	12.20
5 Bagdai & Associates	875.49
6 Bonsai Life Sciences	21.69
7 Bonsai Pharma	130.30
8 Busa & Associates	48.38
9 Cosmas Pharmaceuticals Ltd.	244.16
10 Courtyard Pacifica Hotels Ahemdabad Project Pvt. Ltd.	7.56
11 D C Dani & Associates	11.56
12 D.B.Corp Ltd.	0.70
13 Grishmaben Chandarana	420.00
14 Imran Wadiwala	16.95
15 Incy Healthcare Pvt. Ltd.	126.79
16 Kaps Three Nutra Pvt. Ltd.	165.71
17 Krishna Plastics	6.73
18 Kusumben Rameshbhai Shah	6000.00
19 Medico Healthcare	312.79
20 Mestra Pharma Pvt Ltd.	1298.47
21 Mexon World	116.16
22 Niketaben Kariya	2500.00
23 Nirav Pandya	4630.00
24 Nirav Parmar	240.00
25 Phaedruss Life Science Pvt. Ltd.	224.75
26 Pharma Chemico Laboratories	1.85
27 Plenteous Pharmaceuticals Ltd.	4.00
28 Priyaben Maheshwari	6000.00
29 Radical Healthcare	22.13
30 Rahul Kumar Yadav	90.00

TOTAL C/F

23980.37



M/S APTUS PHARMA PRIVATE LIMITED : RAJKOT

**SUB-NOTES FORMING PART OF THE NOTES TO THE
BALANCE SHEET AS AT 31ST MARCH, 2023**

PARTICULARS

AMT.(RS. IN 100)

SUB NOTE TO NOTE " 14"

SHORT TERM LOANS & ADVANCES (Cont...)

TOTAL B/F

23980.37

OTHER LOANS AND ADVANCES

31 Rashes Govindji Karia		2500.00
32 Rasikbhai C.Rupareliya		3384.00
33 Riddhisa Rasikchandra Rupareliya		3000.00
34 Ritesh Mandaviya		62.67
35 Ritz Pharma		17.15
36 Sagar Joshi		1000.00
37 Three B Health Care Ltd.		1652.22
38 TDS Receivable from NBFC :		
- Bajaj Finance Ltd.	317.25	
- Digicredit	419.06	
- India Bulls	61.85	798.16
39 Sotac Healthcare Pvt.Ltd.		183.88
40 South Asia Fm Ltd.		0.84
41 Spectra Reserch Laboratories		31.39
42 Shiv Digital Sign Rajkot		5.64
43 Tejas Hathi - Salary		34.00
44 Weldew Remedies (p)		48.35
45 Zee Media Corporation		21.19
		36719.86



APTUS PHARMA PRIVATE LIMITED
"Aptus House", Plot No.37, Street No.2,
Rudanagar-2, Near Sarita Vihar Society
Near Gardi Gate, Rajkot
CIN: U24230GJ2010PTC061957

MANAGEMENT REPRESENTATION LETTER

1) Proceedings under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

There are no proceedings initiated or are pending against the company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made thereunder

2) Relationship with Struck off Companies

The Company did not have any transactions with Companies struck off under Section 248 of Companies Act, 2013 or Section 560 of Companies Act, 1956

3) Advance or loan or investment to intermediaries and receipt of funds from intermediaries

The company has not advanced or loaned or invested funds (either borrowed funds or share premium or any other sources or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.

The company has also not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the company shall (i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or (ii) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

4) Undisclosed Income

The Company do not have any transaction which are not recorded in the books of accounts that has been surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 during any of the years.

5) Details of Crypto Currency or Virtual Currency

The Company did not trade or invest in Crypto Currency or virtual currency during the financial year.

6) Property, Plant & Equipment & Intangible Assets

The company has maintained proper records showing full particulars including quantitative details and situation of property, plant and equipment and intangible assets. All property, plant and equipment have not been physical verified by the management during the year but there is regular program of verification and no material discrepancies were noticed on such verification. The Company has not revalued its property, plant and equipment (including right of use asset) during the year.

7) Inventories

The inventories have been physically verified at regular intervals during the year by the management and no discrepancies of 10% or more were noticed on verification between the physical stock and the book records.

8) Loans, Investments, Guarantees, Securities and Advances in nature of loan-

The company has not granted any loans, secured or unsecured, to companies, firms, and limited liability partnership or other parties. It has not made Investments, given guarantee or security or made advances in the nature of loan.

9) Statutory Dues

There are no undisputed statutory dues in arrears as on 31.03.2023.

10) Default in repayment of loans or other borrowings or in the payment of interest thereon to any lender

The company has not defaulted in repayment of loans or other borrowings to any lender. The company is not declared as wilful defaulter by any bank or financial institution or any other lender. Term loans were applied for the purpose for which the loans were obtained. Funds raised on short term basis have not been utilized for long term purposes. The company is not having any subsidiary, joint venture or associate companies.

11) Utilization of Money raised by way of Initial Public Offer/ Further Offer/ Term Loans

The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) during the year. The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.

12) Nidhi Companies

The company is not a "Nidhi Company" as per provision of Nidhi Rules, 2014.

13) Transaction with related parties

The transactions entered by the company with related party are at arms length price and have been disclosed in the financial statements and in the Director's Report.

14) Internal Audit System

The company is not required to appoint Internal Auditor.

15) Non cash Transactions with Directors or persons connected with Director -

The company has not entered any non cash transactions with directors or persons connected with him.

16) Obligation for registration under section 45-IA of the Reserve Bank Of India Act, 1934


The company is not engaged in any financial or investment activity. The Company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration (CoR) from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India.

17) Material Uncertainty

There are no material uncertainty existing as on the date of the audit report that Company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

For APTUS PHARMA PVT. LTD.

Director



Handwritten signature of a director, appearing to be 'H. H. H.', written over two horizontal lines.